Over the past 10 years, U.S. stocks have delivered outstanding returns for investors. The major stock indices such as the Dow Jones Industrial Average , the NASDAQ Composite , and the S&P 500 have all climbed by more than 200% during this boom period. Still, the biggest returns on capital for investors have come from individual stocks. For example, biotech innovators Axsome Therapeutics (NASDAQ: AXSM) and Moderna (NASDAQ: MRNA) , along with electric-car giant Tesla (NASDAQ: TSLA) , have all generated well over 1,000% returns on capital for investors in just the past three years.
Unearthing the next Axsome, Moderna, or Tesla, however, is a not an easy task. The share prices of these companies took flight because they either developed game-changing new products that target huge markets or, in the case of Tesla, created entirely new markets altogether. Axsome, Moderna, and Tesla, in effect, changed the game in their respective fields. And that's why their equities caught fire, thus creating mind-blowing levels of wealth for their early shareholders.
Which companies might be able to follow in the footsteps of these leading innovators? Jasper Therapeutics (NASDAQ: JSPR) and NRx Pharmaceuticals (NASDAQ: NRXP) are two small-cap biotech stocks that may be on the verge of a major growth spurt. In fact, it wouldn't be shocking in the least if their shares rose by 1,000% or perhaps more within the next year. Here's what investors need to know now about these two promising biotech companies.
For further details see:
2 Biotech Stocks Poised for Jaw-Dropping Growth